Supplementary Data 1 from Blockade of a Laminin-411–Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk
Year: 2023
Type: supplementary-materials
Abstract: Tables S1, S2 and S3, and Figure S1. List of used antibodies (Table S1), and immunohistochemical expression of laminin-411 and laminin-421 in human gliomas of various grades (Tables S2 and S3). Expression of laminin-411 vs. laminin-421 increases with glioma grade and in GBMs it correlates with shorter patient survival and faster tumor recurrence (Figure S1)
Authors: Tao Sun, Rameshwar Patil, Anna Galstyan, Dmytro Klymyshyn, Hui Ding, Alexandra Chesnokova, Webster K. Cavenee, Frank B. Furnari, Vladimir A. Ljubimov, Ekaterina S. Shatalova, Shawn Wagner, Debiao Li, Adam N. Mamelak, Serguei I. Bannykh, Chirag G. Patil, Jeremy D. Rudnick, Jethro Hu, Zachary B. Grodzinski, Arthur Rekechenetskiy, Vida Falahatian, Alexander V. Lyubimov, Yongmei L. Chen, Lai S. Leoh, Tracy R. Daniels-Wells, Manuel L. Penichet, Eggehard Holler, Alexander V. Ljubimov, Keith L. Black, Julia Y. Ljubimova
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361898740